BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36138856)

  • 1. Clinical Characterization and Prognostic Value of TPM4 and Its Correlation with Epithelial-Mesenchymal Transition in Glioma.
    Wang J; Yang Y; Du B
    Brain Sci; 2022 Aug; 12(9):. PubMed ID: 36138856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calumenin contributes to epithelial-mesenchymal transition and predicts poor survival in glioma.
    Yang Y; Wang J; Xu S; Shi F; Shan A
    Transl Neurosci; 2021 Jan; 12(1):67-75. PubMed ID: 33623713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BDKRB2 is a novel EMT-related biomarker and predicts poor survival in glioma.
    Yang Y; Wang J; Shi F; Shan A; Xu S; Lv W
    Aging (Albany NY); 2021 Mar; 13(5):7499-7516. PubMed ID: 33686021
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Yang Y; Wang J; Xu S; Lv W; Shi F; Shan A
    Transl Neurosci; 2021 Jan; 12(1):9-19. PubMed ID: 33552590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of TPM4 is associated with worse prognosis and immune infiltration in patients with glioma.
    Li Y; Zhang Y; Wu Z; Sun P
    BMC Neurol; 2023 Jan; 23(1):17. PubMed ID: 36639743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and clinical characterization of ANG expression in gliomas and its association with tumor-related immune response.
    Wang J; Shan A; Shi F; Zheng Q
    Front Med (Lausanne); 2023; 10():1044402. PubMed ID: 37928479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptome profile and clinical characterization of ICOS expression in gliomas.
    Wang J; Shi F; Shan A
    Front Oncol; 2022; 12():946967. PubMed ID: 36276141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of clinical prognosis and molecular immune characterization of tropomyosin 4 in pancreatic cancer.
    Zhou X; Zhu X; Yao J; Wang X; Wang N
    Invest New Drugs; 2021 Dec; 39(6):1469-1483. PubMed ID: 33983530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and Clinical Characterization of LIGHT/TNFSF14 Expression at Transcriptional Level
    Yang Y; Lv W; Xu S; Shi F; Shan A; Wang J
    Front Mol Biosci; 2021; 8():567327. PubMed ID: 34513918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value and Biological Function of Galectins in Malignant Glioma.
    Zhu H; Liu D; Cheng L; Liu J; Wang G; Li H; Zhang Y; Mi H; Zhang S; Shu K; Yu X
    Front Oncol; 2022; 12():834307. PubMed ID: 35814469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomics and Prognosis Analysis of Epithelial-Mesenchymal Transition in Glioma.
    Tao C; Huang K; Shi J; Hu Q; Li K; Zhu X
    Front Oncol; 2020; 10():183. PubMed ID: 32154177
    [No Abstract]   [Full Text] [Related]  

  • 12. NKCC1 involvement in the epithelial-to-mesenchymal transition is a prognostic biomarker in gliomas.
    Sun H; Long S; Wu B; Liu J; Li G
    PeerJ; 2020; 8():e8787. PubMed ID: 32211242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial-mesenchymal transition is the main way in which glioma-associated microglia/macrophages promote glioma progression.
    He X; Guo Y; Yu C; Zhang H; Wang S
    Front Immunol; 2023; 14():1097880. PubMed ID: 36969175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of overall survival-EMT-immune cell infiltration genes predict the prognosis of glioma.
    Zheng L; He JJ; Zhao KX; Pan YF; Liu WX
    Noncoding RNA Res; 2024 Jun; 9(2):407-420. PubMed ID: 38511063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma.
    Liu J; Gao L; Zhan N; Xu P; Yang J; Yuan F; Xu Y; Cai Q; Geng R; Chen Q
    J Exp Clin Cancer Res; 2020 Jul; 39(1):137. PubMed ID: 32677981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role Played by SLUG, an Epithelial-Mesenchymal Transition Factor, in Invasion and Therapeutic Resistance of Malignant Glioma.
    Oh SJ; Ahn EJ; Kim O; Kim D; Jung TY; Jung S; Lee JH; Kim KK; Kim H; Kim EH; Lee KH; Moon KS
    Cell Mol Neurobiol; 2019 Aug; 39(6):769-782. PubMed ID: 31011939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma.
    Chai RC; Wang N; Chang YZ; Zhang KN; Li JJ; Niu JJ; Wu F; Liu YQ; Wang YZ
    Cancer Cell Int; 2019; 19():155. PubMed ID: 31171919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-induced PLOD2 promotes proliferation, migration and invasion via PI3K/Akt signaling in glioma.
    Song Y; Zheng S; Wang J; Long H; Fang L; Wang G; Li Z; Que T; Liu Y; Li Y; Zhang X; Fang W; Qi S
    Oncotarget; 2017 Jun; 8(26):41947-41962. PubMed ID: 28410212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
    Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
    Front Oncol; 2021; 11():611038. PubMed ID: 33937022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.